Role of downregulated ADARB1 in lung squamous cell carcinoma
- PMID: 32016472
- PMCID: PMC7003044
- DOI: 10.3892/mmr.2020.10958
Role of downregulated ADARB1 in lung squamous cell carcinoma
Abstract
Non‑small cell lung cancer (NSCLC) is prevalent worldwide. Lung squamous cell carcinoma (LUSC) is one of the main subtypes of NSCLC yet, currently, few biomarkers are available for the diagnosis of LUSC. The present study aimed to investigate the expression and role of adenosine deaminase RNA specific B1 (ADARB1) in lung squamous cell carcinoma (LUSC). Integrative bioinformatics analysis was used to identify the effects of ADARB1 expression on the occurrence and prognosis of LUSC. The expression of ADARB1 was further examined by immunohistochemistry (IHC). Bioinformatics analysis suggested that ADARB1 was downregulated in LUSC, serving as a potential tumor suppressor, and these results were verified by IHC performed on a lung cancer tissue array. Clinical studies suggested that ADARB1 expression and methylation levels were significantly associated with patient characteristics in LUSC. Moreover, ADARB1 global methylation levels were upregulated in LUSC tissues compared with normal lung tissues. Higher methylation levels of cg24063645 were associated with shorter overall survival time of patients with LUSC. A negative correlation was identified between ADARB1 and epidermal growth factor receptor (EGFR) expression in LUSC. Using the Gene Expression Omnibus database, it was suggested that the expression of ADARB1 in LUSC was significantly different compared with that in lung adenocarcinoma. Furthermore, protein‑protein interactions were studied and a biological process annotation analysis was conducted. The present study suggested that ADARB1 was downregulated in LUSC; therefore, ADARB1 may serve as a specific biomarker and a potential therapeutic target for LUSC.
Keywords: adenosine deaminase RNA specific B1; expression; methylation; survival; therapeutics.
Figures






Similar articles
-
Function of low ADARB1 expression in lung adenocarcinoma.PLoS One. 2019 Sep 6;14(9):e0222298. doi: 10.1371/journal.pone.0222298. eCollection 2019. PLoS One. 2019. PMID: 31491024 Free PMC article.
-
Differential MUC22 expression by epigenetic alterations in human lung squamous cell carcinoma and adenocarcinoma.Oncol Rep. 2021 May;45(5):78. doi: 10.3892/or.2021.8029. Epub 2021 Mar 31. Oncol Rep. 2021. PMID: 33786615 Free PMC article.
-
Integrative analysis of DNA methylation-driven genes for the prognosis of lung squamous cell carcinoma using MethylMix.Int J Med Sci. 2020 Mar 5;17(6):773-786. doi: 10.7150/ijms.43272. eCollection 2020. Int J Med Sci. 2020. PMID: 32218699 Free PMC article.
-
Primary Lung Squamous Cell Carcinoma With Intestinal Metastasis: A Case Report and Literature Review.Clin Respir J. 2024 Aug;18(8):e13817. doi: 10.1111/crj.13817. Clin Respir J. 2024. PMID: 39118303 Free PMC article. Review.
-
Clinicopathological implications of lncRNAs, immunotherapy and DNA methylation in lung squamous cell carcinoma: a narrative review.Transl Cancer Res. 2021 Dec;10(12):5406-5429. doi: 10.21037/tcr-21-1607. Transl Cancer Res. 2021. PMID: 35116387 Free PMC article. Review.
Cited by
-
Integration of TE Induces Cancer Specific Alternative Splicing Events.Int J Mol Sci. 2022 Sep 18;23(18):10918. doi: 10.3390/ijms231810918. Int J Mol Sci. 2022. PMID: 36142830 Free PMC article. Review.
-
Insights of fibroblast growth factor receptor 3 aberrations in pan-cancer and their roles in potential clinical treatment.Aging (Albany NY). 2021 Jun 23;13(12):16541-16566. doi: 10.18632/aging.203175. Epub 2021 Jun 23. Aging (Albany NY). 2021. PMID: 34160364 Free PMC article.
-
Downregulated ADARB1 Facilitates Cell Proliferation, Invasion and has Effect on the Immune Regulation in Ovarian Cancer.Front Bioeng Biotechnol. 2021 Dec 23;9:792911. doi: 10.3389/fbioe.2021.792911. eCollection 2021. Front Bioeng Biotechnol. 2021. PMID: 35004651 Free PMC article.
References
-
- Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet. 2016;387:1540–1550. doi: 10.1016/S0140-6736(15)01281-7. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous